[RESEARCH BLOG] · 2026-09-23
CG Oncology (CGON) Receives a **BUY** Signal While the Market Stays in a Bear Regime – LOPJLB Research Brief
By Pierre Brunelle · Founder & Research Lead
CG Oncology’s common stock closed at $77.74, down 0.65 % as of 2026‑09‑22 (Tuesday, US session). LOPJLB’s proprietary scanner now flags the ticker with a BUY directional signal (Score 5) even though the broader market regime remains BEAR for the past 13 days.
Recent News Flow
-
September 20, 2026 – Insider activity surfaced when a CG Oncology director sold $72,980 worth of shares, according to a filing reported by DefenseWorld. The transaction, disclosed in a Form 4, represented a modest portion of the director’s holdings and was executed at an average price near the current market level. While insider sales can sometimes signal concerns, the modest size and lack of accompanying commentary suggest a routine portfolio rebalancing rather than a strategic shift.
→ Insider Selling: CG Oncology (NASDAQ:CGON) Director Sells $72,980.00 in Stock -
September 14, 2026 – CG Oncology presented at the Morgan Stanley 24th Annual Global Healthcare Conference. Management highlighted progress in its Phase 2 trial of cretostimogene for high‑risk non‑muscle‑invasive bladder cancer (NMIBC) after BCG failure, emphasizing a favorable safety profile and early signals of efficacy. The presentation also outlined a roadmap toward a Phase 3 registration trial, positioning the biotech for a potential U.S. market entry within the next 12‑18 months.
→ CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript -
September 5, 2026 – Jupiter Topco LLC acquired 23,000 CG Oncology shares in a block trade, valued at roughly $1.79 million based on the closing price. The purchase placed Jupiter Topco among the larger institutional holders, hinting at continued confidence in the company’s pipeline despite recent earnings volatility.
→ 23,000 Shares in CG Oncology, Inc. $CGON Purchased by Jupiter Topco LLC -
September 2, 2026 – Schäffer’s Research listed CG Oncology among “15 Stocks to Watch With Short‑Squeeze Potential.” The analyst cited the company’s low float, recent insider transactions, and historically high short‑interest ratio as catalysts that could amplify price moves if buying pressure intensifies. The piece cautioned investors to monitor volume spikes and regulatory updates closely.
→ 15 Stocks to Watch With Short Squeeze Potential -
September 2, 2026 – CG Oncology announced that it would present at several investor conferences throughout September, according to a GlobeNewswire release. Appearances are slated at the J.P. Morgan Healthcare Conference, the BIO International Convention, and a regional biotech summit in Boston. Management indicated these forums will be used to update investors on trial data, discuss partnership opportunities, and outline capital‑raising strategies for the upcoming Phase 3 study.
→ CG Oncology to Present at Upcoming Investor Conferences in September
Fundamentals and Valuation
CG Oncology operates in the biotechnology sector, focusing on an oncolytic immunotherapy platform targeting bladder cancer. The company’s market capitalization stands at $6.86 billion, reflecting a valuation that remains heavily weighted toward future growth expectations rather than current earnings.
Key valuation multiples (TTM unless otherwise noted):
| Metric | Value |
|---|---|
| P/E (TTM) | -28.79 |
| P/B | 6.66 |
| EV/EBITDA | -30.80 |
| ROE | -25.20 % |
| Gross Margin | -82.69 % |
| Analyst Target | $87.20 |
Revenue & Earnings Trajectory
| Fiscal Year | Revenue | EPS (basic) | Free Cash Flow |
|---|---|---|---|
| 2021 | $10.36 M | -$0.28 | -$13.75 M |
| 2022 | $0.191 M | -$0.66 | -$29.82 M |
| 2023 | $0.204 M | -$1.02 | -$45.68 M |
| 2024 | $1.139 M | -$1.41 | -$78.95 M |
| 2025 | $4.04 M | -$2.08 | -$132.48 M |
Revenue has risen from modest collaboration fees to milestone payments tied to the cretostimogene program, while EPS has deepened as R&D spend accelerates. The ‑$13.25 M free‑cash‑flow outflow in 2025 underscores the need for continued capital raises.
Historical Margin Compression
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2021 | 99.9 % | -121.7 % | -124.0 % |
| 2022 | 92.15 % | -18,453.4 % | -18,556.5 % |
| 2023 | -22,327.5 % | -27,180.9 % | -23,827.0 % |
| 2024 | -7,108.2 % | -10,067.2 % | -7,729.5 % |
| 2025 | -15.02 % | -4,722.1 % | -3,985.0 % |
The steepening margins are typical for a firm transitioning from early‑stage collaborations to late‑stage trial execution, where cash burn accelerates ahead of any product revenue.
ETF Ownership
CG Oncology’s shares are held across a modest set of thematic and sector‑focused exchange‑traded funds. The ten largest ETF holders collectively own roughly 12 % of the float, with the most concentrated positions found in biotech‑focused funds.
| ETF (Ticker) | Weight % |
|---|---|
| SBIO | 3.41 % |
| CANC | 2.76 % |
| XBI | 1.26 % |
| WDNA | 0.85 % |
| FNY | 0.67 % |
| JDOC | 0.64 % |
| AGNG | 0.41 % |
| GDOC | 0.36 % |
| LABU | 0.28 % |
| IWM | 0.17 % |
Concentrated ETF ownership can amplify price movements when fund managers rebalance or when the ETFs experience inflows/outflows tied to sector rotations. In a bear‑market backdrop, biotech‑specific ETFs may provide a stabilizing floor, as these funds often maintain exposure to high‑potential clinical‑stage assets despite broader weakness.
LOPJLB Signal Read
The LOPJLB scanner currently flags CGON with a BUY directional signal (Score 5) while the overall market regime is classified as BEAR for the past 13 days. The composite PERF score of 53.00 and FUND quality score of 4.68 indicate that the model sees relative strength in the stock’s price action and underlying fundamentals, even as earnings remain negative.
The stock’s Value (8.00), Growth (4.00), GARP (4.80) and Quality (4.68) metrics combine to produce a Balanced archetype, suggesting that CG Oncology sits at the intersection of value‑oriented pricing and growth‑driven upside potential. Investors looking for exposure to late‑stage oncology pipelines may find the signal aligns with a risk‑adjusted view that the upcoming Phase 3 trial could serve as a catalyst.
For a deeper dive into the methodology behind the signal, see the interactive chart above the article and the full stock detail page. Learn more about the model’s construction at LOPJLB’s methodology page.
Explore further
- Detailed CG Oncology profile: https://www.lopjlb.com/stock/CGON
- Earnings‑related filings and transcripts (if applicable): https://www.lopjlb.com/stock/CGON/earnings.md
- Run your own screen for similar opportunities: https://www.lopjlb.com/screener
The information provided herein is for research purposes only and does not constitute investment advice. All investors should conduct their own due diligence and consider their risk tolerance before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.